Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
January 25, 2024 12:03 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its...
Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
May 25, 2023 10:38 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its...
Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel
April 20, 2023 07:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement...
Kane Biotech Announces 510(k) Submission for its coactiv+™ Antimicrobial Hydrogel
November 03, 2022 07:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that it has recently submitted a 510(k) premarket...